PMID- 32725456
OWN - NLM
STAT- MEDLINE
DCOM- 20220113
LR  - 20220113
IS  - 1573-6830 (Electronic)
IS  - 0272-4340 (Linking)
VI  - 41
IP  - 7
DP  - 2021 Oct
TI  - Valproic Acid: A Potential Therapeutic for Spinal Cord Injury.
PG  - 1441-1452
LID - 10.1007/s10571-020-00929-9 [doi]
AB  - The lack of an effective pharmaceutical agent for spinal cord injury (SCI) is a 
      current problematic situation for clinicians, as the rate of motor vehicle 
      accidents among young adults is on the rise. SCI contributes to the high 
      disability rate. Presently, evidences detailing the precise pathological 
      mechanisms in SCI are limited, compounding to the unavailability of an effective 
      treatment method. Surgery, though not a complete curative method, is useful in 
      managing some of the associated symptoms of secondary SCI. Autophagy and 
      inflammation are contributive factors to both exacerbation and improvement of 
      SCI. The mammalian target of rapamycin (mTOR) signaling pathway is a key player 
      in the regulation of inflammatory response and autophagy. Valproic acid (VPA), a 
      clinically used antiepileptic drug, has been suggested to improve neurological 
      conditions, including SCI. This report reviewed the correlation between mTOR and 
      autophagy, as well as autophagy's role and the therapeutic effects of VPA in SCI. 
      VPA regulates autophagy by potentially inhibiting mTORC1, a complex of mTOR, 
      while also hindering inflammatory response. Conclusively, an effective treatment 
      for SCI could lie in the timely regulation of mTOR signaling pathway, and VPA 
      could be the potential drug that improves SCI owing to its propensity to regulate 
      the mTOR signaling pathway.
CI  - (c) 2020. Springer Science+Business Media, LLC, part of Springer Nature.
FAU - Zhou, Conghui
AU  - Zhou C
AUID- ORCID: 0000-0001-8286-810X
AD  - Department of Histology and Embryology, Medical College, Shaoxing University, 
      Shaoxing, 312000, Zhejiang Province, China.
FAU - Hu, Songfeng
AU  - Hu S
AUID- ORCID: 0000-0002-4575-731X
AD  - Department of Orthopedics, Shaoxing Hospital of Traditional Chinese Medicine, 
      Shaoxing, 312000, Zhejiang Province, China.
FAU - Botchway, Benson O A
AU  - Botchway BOA
AUID- ORCID: 0000-0001-9732-7904
AD  - Institute of Neuroscience, Zhejiang University School of Medicine, Hangzhou, 
      China.
FAU - Zhang, Yong
AU  - Zhang Y
AUID- ORCID: 0000-0002-2502-2703
AD  - Department of Histology and Embryology, Medical College, Shaoxing University, 
      Shaoxing, 312000, Zhejiang Province, China.
FAU - Liu, Xuehong
AU  - Liu X
AUID- ORCID: 0000-0003-4325-6762
AD  - Department of Histology and Embryology, Medical College, Shaoxing University, 
      Shaoxing, 312000, Zhejiang Province, China. liuxueh6588@126.com.
LA  - eng
GR  - LY19H170001/Natural Science Foundation of Zhejiang Province/
PT  - Journal Article
PT  - Review
DEP - 20200728
PL  - United States
TA  - Cell Mol Neurobiol
JT  - Cellular and molecular neurobiology
JID - 8200709
RN  - 614OI1Z5WI (Valproic Acid)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Autophagy/drug effects
MH  - Recovery of Function/*drug effects
MH  - Spinal Cord/drug effects/metabolism
MH  - Spinal Cord Injuries/*drug therapy/pathology
MH  - TOR Serine-Threonine Kinases/*drug effects/metabolism
MH  - Valproic Acid/metabolism/*pharmacology
OTO - NOTNLM
OT  - Autophagy
OT  - Inflammation
OT  - Spinal cord injury
OT  - Valproic acid
OT  - mTOR signaling pathway
EDAT- 2020/07/30 06:00
MHDA- 2022/01/14 06:00
CRDT- 2020/07/30 06:00
PHST- 2020/04/29 00:00 [received]
PHST- 2020/07/20 00:00 [accepted]
PHST- 2020/07/30 06:00 [pubmed]
PHST- 2022/01/14 06:00 [medline]
PHST- 2020/07/30 06:00 [entrez]
AID - 10.1007/s10571-020-00929-9 [pii]
AID - 10.1007/s10571-020-00929-9 [doi]
PST - ppublish
SO  - Cell Mol Neurobiol. 2021 Oct;41(7):1441-1452. doi: 10.1007/s10571-020-00929-9. 
      Epub 2020 Jul 28.